Kolopp-Sarda M N, Béné M E, Allaire J M, Perruchet A M, Faure G C
Laboratoire d'Immunologie, Faculté de Médecine, Nancy, France.
Int J Immunopharmacol. 1997 Mar;19(3):181-6. doi: 10.1016/s0192-0561(97)00018-0.
The kinetics of specific IgA mucosal responses was assessed in 12 healthy volunteers over 3 weeks of treatment by oral administration of an immunostimulant, Ribomunyl, composed of ribosomes from the four bacteria Streptococcus pyogenes, Streptococcus pneumoniae, Klebsiella pneumoniae and Haemophilus influenzae. The levels of IgA specific for these four bacteria increased after each immunization and, after the third week of treatment, were significantly higher than baseline day 0 values. This study demonstrates that oral ribosomal immunostimulation results in the production of specific salivary antibodies liable to recognize whole bacteria antigens, and therefore likely to confer protection. The kinetic analysis performed also demonstrates the rapidity of specific mucosal immune responses after oral stimulation in man, a feature still seldom explored.
通过口服一种免疫刺激剂——力保肪宁（Ribomunyl），对12名健康志愿者进行了为期3周的治疗，评估了特异性IgA黏膜反应的动力学。力保肪宁由化脓性链球菌、肺炎链球菌、肺炎克雷伯菌和流感嗜血杆菌这四种细菌的核糖体组成。每次免疫后，针对这四种细菌的特异性IgA水平均有所升高，且在治疗第三周后，显著高于第0天的基线值。这项研究表明，口服核糖体免疫刺激可导致产生易于识别全菌抗原的特异性唾液抗体，因此可能具有保护作用。所进行的动力学分析还表明，人体口服刺激后特异性黏膜免疫反应迅速，这一特点仍鲜少被研究。
